United Kingdom - English - myHealthbox

mercury pharmaceuticals limited - gliclazide - modified-release tablet - 30mg - sulphonamides, urea derivative - it is indicated in adults for treatment of non-insulin dependent diabetes (type 2) when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.

United Kingdom - English - myHealthbox

mercury pharmaceuticals limited - gliclazide - modified-release tablet - 60mg - sulphonamides, urea derivative - it is indicated in adults for treatment of non-insulin dependent diabetes (type 2) when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.

Ireland - English - HPRA (Health Products Regulatory Authority)

crescent pharma limited - prednisolone - tablets gastro-resistant - 2.5 milligram - prednisolone - glucocorticoids - it is indicated for: allergy and anaphylaxis; arteritis/collagenosis; blood disorders; cardiovascular disorders; endocrine disorders; gastro-intestinal disorders; hypercalcaemia; infections (with appropriate chemotherapy); muscular disorders; neurological disorders; ocular disease; renal disorders; respiratory disease; rheumatic disorders; skin disorders.

Ireland - English - HPRA (Health Products Regulatory Authority)

crescent pharma limited - prednisolone - tablets gastro-resistant - 5 milligram - prednisolone - glucocorticoids - it is indicated for: allergy and anaphylaxis; arteritis/collagenosis; blood disorders; cardiovascular disorders; endocrine disorders; gastro-intestinal disorders; hypercalcaemia; infections (with appropriate chemotherapy); muscular disorders; neurological disorders; ocular disease; renal disorders; respiratory disease; rheumatic disorders; skin disorders.

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin i - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting - humulin m3 - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting - humulin m3 - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis.

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting - humulin m3 - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis